Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting

On April 14, 2023 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported its participation in the upcoming 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place in Orlando, Florida from April 14 through April 19, 2023, where VAL-083 data will be presented (Press release, Kintara Therapeutics, APR 14, 2023, View Source [SID1234630086]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data Presentations:

Session Title: Late-Breaking Research: Clinical Research 1 / Endocrinology
Poster Section 34, Presentation Time: Monday, April 17, 2023 – 1:30 to 5:00 p.m. ET

Abstract LB126: RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access – case reports

The abstract describes two patient case reports, one with ependymoma and one with diffuse midline glioma, treated with VAL-083 under an expanded access program. The cases highlight that VAL-083 may be a treatment option for recurrent RELA fusion-positive ependymoma and diffuse midline glioma refractory to other treatments. Safety and efficacy data will be updated at the poster presentation at the meeting.

Abstract LB127: VAL-083 in patients with recurrent glioblastoma treated under expanded access program

The abstract reports on background characteristics, and safety and efficacy measures, from 24 patients with recurrent GBM treated with VAL-083 under an expanded access program. Use of VAL-083 continues to show benefit in the treatment of GBM patients who have had multiple recurrences and have limited therapeutic options. This information will be updated in the poster presentation at the meeting.